The Efficacy Ratio Of Percutaneous Vertebroplasty Combined With Geftiinib And Geftiinib Alone In The Treatment Of EGFR-positive NSCLC Spinal Metastatic Tumor

ObjectiveTo compare The efficacy ratio of percutaneous vertebroplasty combined with geftiinib and geftiinib alone in the treatment of EGFR-positive NSCLC spinal metastatic tumor.MethodsRetrospective analysis was performed on patients with EGFR-positive NSCLC spinal metastatic tumor admitted to orthopedics and pulmonary oncology department of PLA 307 hospital from December 2011 to June 2017.According to different treatment methods,patients treated with PVP combined with TKIs targeting drug gefitinib were divided into group A(30 cases),Group B(40 patients)were treated with TKIs targeting drug gefitinib,The age,sex and other general information of patients in the two groups were collected.The medical evaluation effect of gefitinib in both groups was SD or above.Visual analogue score of pain,physical condition score and spinal tumor instability score were used to score the pain and physical condition of the patients in the two groups before treatment,1 month,3 months and 6 months after treatment,We use cox proportional risk model to analyze the correlation between patient survival and visceral metastasis,systemic internal medicine,number of diseased vertebrae,and pretreatment physical status.ResultsThere baseline data between the two groups has no remarkable difference(P >0.05).VAS score of patients in group A after PVP was significantly lower than that before treatment(P < 0.05),VAS scores of patients in group B at 1,3 and 6 months after TKIs treatment were statistically significant compared with those before treatment(P <90.05).The ECOG score of physical condition of patients in the two groups at 3 months and 6 months after treatment was significantly higher than that before treatment(P <0.05).The VAS score in group A was obviously lower than group B at 1 and 3 months after treatment(P < 0.05),However,after 6 months of treatment,there results showed that the VAS score between the two groups has no significant difference(P > 0.05).Physical fitness of patients in group A was significantly improved at 1,3 and 6 months after treatment(P < 0.05),Physical fitness of patients in group B showed no significant change one month after treatment(P > 0.05),3 months and 6 months after treatment,the physical fitness of the patients was higher than before(P < 0.05).At 1 month after treatment,we found in physical fitness between group A and group B has a statistically significant difference(P < 0.05),the results in group A was better than group B;While there was no significant difference in physical fitness scores between the two groups at3 and 6 months after treatment(P > 0.05).At the same time,the results showed no difference between the two groups in survival(P > 0.05).Multivariate Cox proportional risk model analysis showed that visceral metastasis,systemic internal medicine,number of diseased vertebral bodies and physical condition were important prognostic factors may have effect on the survival of patients with spinal metastatic tumor.ConclusionPVP combined with geftiinib treatment and geftiinib treatment of EGFR-positive NSCLC spinal metastatic tumor have clinical efficacy.The same two treatments can alleviate pain,increase physical fitness and improve the quality of life of patients,but there is no statistical significance between the two treatments.PVP combined with geftiinib in the treatment of EGFR-positive NSCLC spinal metastatic tumor can more quickly relieve the pain of patients,improve the stability of the patient’s spine,and improve the quality of life of patients than geftiinib.Visceral metastasis,systemic internal medicine,number of diseased vertebral bodies and physical condition before treatment are vital important prognostic factors for the survival of patients with spinal metastatic tumor.